Targeting DNA checkpoint kinases in cancer therapy

Related Experiment Video

Updated: Aug 31, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Bin-Bing S Zhou1, Hilary J Anderson, Michel Roberge

  • 1Drug Discovery Biology, Incyte Genomics, Inc.; Newark, Delaware 19714, USA. bzhou@incyte.com

Cancer Biology & Therapy
|September 26, 2003
PubMed

Insights

The DNA damage response involves cell cycle arrest, apoptosis, and DNA repair activation. Checkpoint kinases like ATM, ATR, Chk1, and Chk2 are key targets for novel cancer therapies.

Area of Science:

  • Molecular Biology
  • Cell Biology
  • Oncology

Background:

  • The DNA damage response (DDR) is crucial for maintaining genomic stability.
  • Key components of the DDR include cell cycle checkpoints and apoptosis.
  • DNA checkpoint kinases play a central role in orchestrating the DDR.

Purpose of the Study:

  • To review current knowledge on DNA checkpoint kinases.
  • To discuss the role of these kinases in the mammalian DNA damage response.
  • To explore the potential of checkpoint kinases as therapeutic targets in cancer treatment.

Main Methods:

  • Literature review and synthesis of current research.
  • Discussion of signal transduction pathways involving ATM, ATR, Chk1, and Chk2.
  • Analysis of therapeutic hypotheses related to targeting these kinases.

Main Results:

  • Four major DNA checkpoint kinases (ATM, ATR, Chk1, Chk2) have been identified.
  • These kinases are integral to the mammalian DNA damage response pathway.
  • Checkpoint kinases represent promising targets for cancer drug development.

Conclusions:

  • Targeting DNA checkpoint kinases offers a promising strategy for enhancing cancer therapies.
  • Further research into therapeutic hypotheses could lead to improved treatment outcomes.
  • Understanding the DDR pathway is vital for developing effective cancer treatments.

More Related Videos

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
DNA Damage can Stall the Cell Cycle02:36

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
DNA Damage Can Stall the Cell Cycle02:36

DNA Damage Can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...